Key result
Loss of pulsatility during Impella support is linked to ~2.2-fold higher 30-day mortality.
Why the study?
Loss of pulsatility during Impella support reflects ventriculo-arterial uncoupling and profound ventricular unloading, but its clinical and prognostic implications remain poorly defined.
Does the occurrence of loss of pulsatility during Impella support increase 30-day and long-term all-cause mortality in patients with cardiogenic shock or undergoing complex high-risk indicated PCI?
Observational (n=593)
Yes
Does the occurrence of loss of pulsatility during Impella support increase 30-day and long-term all-cause mortality in patients with cardiogenic shock or undergoing complex high-risk indicated PCI?
Answers are grounded in this paper and cite their sources.
Loss of pulsatility occurs in 28% of patients during Impella support and independently predicts more than double the odds of 30-day mortality, signaling a need for immediate hemodynamic reassessment.
Background Percutaneous microaxial flow pumps such as Impella are increasingly used in cardiogenic shock (CS) and complex high-risk indicated PCI (CHIP). Loss of pulsatility (LoP) during Impella support, defined as a transient reduction in pulse pressure <20 mmHg for >5 seconds, reflects ventriculo-arterial uncoupling and profound ventricular unloading. However, its clinical and prognostic implications remain poorly defined. Methods We analyzed data from the international multicentric IMMERGE registry including patients treated with contemporary Impella devices (CP, 5.0, 5.5) between January 2013 and January 2025. Among 1019 enrolled patients, LoP data were available in 593 cases. Patients were stratified according to the occurrence of LoP during support. Multivariable logistic regression assessed predictors of LoP and its association with 30-day mortality. Cox proportional hazards models evaluated long-term mortality (up to 1 year). Hemodynamic and biochemical trajectories were analyzed using linear mixed-effects models. Results LoP occurred in 170 of 593 patients (28%). It was more frequent in patients presenting with CS (64.1% vs. 37.8%, p<0.001), cardiac arrest (40.8% vs. 12.8%, p<0.001), and acute vessel occlusion (44.0% vs. 22.9%, p<0.001). Independent predictors of LoP were cardiogenic shock (OR 1.62, p=0.01), cardiac arrest (OR 2.89, p<0.001), and acute vessel occlusion (OR 1.56, p<0.001). At 30 days, LoP was associated with significantly higher all-cause mortality (43.5% vs. 20.0%, p<0.001), acute kidney injury, major bleeding, and sepsis. After adjustment, LoP independently predicted 30-day mortality (OR 2.2, 95% CI 1.2–3.8, p=0.007), together with CS (OR 9.5, p<0.001). Hemodynamically, LoP patients exhibited lower SvO₂, higher lactate levels, lower systolic blood pressure, higher heart rate, and increased vasoactive support requirements. At a mean follow-up of 499±100 days, crude all-cause mortality remained higher in the LoP group (54.7% vs. 35.6%, p<0.001), but LoP was not independently associated with long-term mortality after multivariable adjustment (HR 1.19, p=0.53). Age, CKD, cardiac arrest, and CS were independent predictors of long-term mortality. Conclusions Loss of pulsatility during Impella support is frequent and identifies a subgroup of critically ill patients with markedly increased short-term mortality and end-organ complications. LoP independently predicts 30-day mortality but not long-term mortality after adjustment. Recognition of LoP should prompt immediate hemodynamic reassessment and intensified clinical management. Further studies are warranted to clarify mechanistic pathways and evaluate targeted mitigation strategies.
No takes yet. Share an insight, caveat, or question.
Giacobbe et al. (2026) conducted an observational in Cardiogenic shock and complex high-risk indicated PCI treated with Impella (n=593). Loss of pulsatility (transient reduction in pulse pressure <20 mmHg for >5 seconds) during Impella support vs. Preserved pulsatility during Impella support was evaluated on 30-day all-cause mortality (OR 2.2, 95% CI 1.2-3.8, p=0.007). Loss of pulsatility during Impella support independently predicted higher 30-day all-cause mortality but not long-term mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: